01 abril 2015

AMERICAN HEART JOURNAL. Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study

Wei Jiang, MD, Stephen H. Boyle, PhD, Thomas L. Ortel, MD, PhD, Zainab Samad, MD, Eric J. Velazquez, MD, Robert W. Harrison, MD, Jennifer Wilson, BA, Cynthia Kuhn, PhD, Redford B. Williams, MD, Christopher M. O’Connor, MD, Richard C. Becker, MD

Background: Mental stress-induced myocardial ischemia (MSIMI) is common in patients with ischemic heart disease (IHD) and associated with a poorer cardiovascular prognosis. Platelet hyperactivity is an important factor in acute coronary syndrome. This study examined associations between MSIMI and resting and mental stress-induced platelet activity.

01 abril 2015

AMERICAN HEART JOURNAL. Cardiac arrest and clinical characteristics, treatments and outcomes among patients hospitalized with ST-elevation myocardial infarction in contemporary practice: A report from the National Cardiovascular Data Registry

Michael C. Kontos, MD, Benjamin M. Scirica, MD, Anita Y. Chen, MS, Laine Thomas, PhD, Monique L. Anderson, MD, Deborah B. Diercks, MD, James G. Jollis, MD, Matthew T. Roe, MD on behalf of the NCDR

Background: Cardiac arrest (CA) is a major complication of patients with ST-elevation myocardial infarction (STEMI). Its prevalence and prognostic impact in contemporary US practice has not been well assessed.

01 abril 2015

AMERICAN HEART JOURNAL. A nationwide survey on perception, experience, and expectations of hybrid coronary revascularization among top-ranked US hospitals

Ralf E. Harskamp, MD, Michael E. Halkos, MD, MS, Ying Xian, MD, PhD, Molly A. Szerlip, MD, Robert S. Poston, MD, Stephanie L. Mick, MD, Renato D. Lopes, MD, PhD, Jan G. Tijssen, PhD, Robbert J. de Winter, MD, PhD, Eric D. Peterson, MD, MPH

Background: Hybrid coronary revascularization (HCR) combines a surgical and percutaneous approach for treatment of multivessel coronary artery disease.

01 abril 2015

AMERICAN HEART JOURNAL. A novel coronary angiography index (DILEMMA score) for prediction of functionally significant coronary artery stenoses assessed by fractional flow reserve: A novel coronary angiography index

Dennis T.L. Wong, MBBS (Hons), PhD, Om Narayan, MBBS (Hons), Brian S.H. Ko, MBBS (Hons), PhD, Darryl P. Leong, MBBS (Hons), MPH, PhD, Sujith Seneviratne, MBBS, Elizabeth L. Potter, MBBS, James D. Cameron, MBBS, MD, Ian T. Meredith, MBBS (Hons), PhD, Yuvaraj Malaiapan, MBBS

Background: Angiographic evaluation of diameter stenosis has modest predictive value for functionally significant coronary artery stenoses as assessed by fractional flow reserve (FFR). Lesion length and assessment of area of myocardium at risk (Bypass Angioplasty Revascularization Investigation [BARI] Myocardial Jeopardy Index [MJI]) subtended by the stenotic coronary arteries are also predictors of functionally significant coronary artery stenoses. We sort to assess the diagnostic accuracy of DILEMMA score, which combines minimal lumen diameter (MLD), lesion length, and BARI MJI in prediction of significantly reduced FFR (≤0.8).

01 abril 2015

AMERICAN HEART JOURNAL. Sensitive troponin assays in patients with suspected acute coronary syndrome: Results from the multicenter rule out myocardial infarction using computer assisted tomography II trial

James L. Januzzi, MD, Umesh Sharma, MD, Pearl Zakroysky, MS, Quynh A. Truong, MD, Pamela K. Woodard, MD, J. Hector Pope, MD, Thomas Hauser, MD, Thomas Mayrhofer, MD, J. Toby Nagurney, MD, David Schoenfeld, PhD, W.Frank Peacock, MD, Jerome L. Fleg, MD, Stephen Wiviott, MD, Peter S. Pang, MD, James Udelson, MD, Udo Hoffmann, MD

Background: Sensitive troponin (Tn) assays have been developed for the evaluation of patients with suspected acute coronary syndrome (ACS). We sought to compare the performance of a commercially available sensitive Tn I (sTnI) and precommercial highly sTnI (hsTnI) method to conventional Tn (cTn) assays.

01 abril 2015

AMERICAN HEART JOURNAL. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)

. Michael Gibson, MS, MD, Roxana Mehran, MD, Christoph Bode, MD, Johnathan Halperin, MD, Freek Verheugt, MD, Peter Wildgoose, PhD, Martin van Eickels, MD, Gregory Y.H. Lip, MD, Marc Cohen, MD, Steen Husted, MD, Eric Peterson, MD, Keith Fox, MD

Background: Guidelines recommendations regarding anticoagulant therapy after percutaneous coronary intervention (PCI) among patients with atrial fibrillation (AF) rely on retrospective, nonrandomized observational data. Currently, patients are treated with triple-therapy (dual antiplatelet therapy [DAPT] + oral anticoagulation therapy), but neither the duration of DAPT nor the level of anticoagulation has been studied in a randomized fashion. Recent studies also suggest dual pathway therapy with clopidogrel plus oral anticoagulation therapy may be superior, and other studies suggest that novel oral anticoagulants such as rivaroxaban may further improve patient outcomes.

01 mayo 2015

AMERICAN HEART JOURNAL. The proxy of renal function that most accurately predicts short- and long-term outcome after acute coronary syndrome

Katia Orvin, MDd, Alon Eisen, MDd, Ilan Goldenberg, MD, Ateret Farkash, Nir Shlomo, MPH, Natalie Gevrielov-Yusim, MSc, Zaza Iakobishvili, MD, PhD, David Hasdai, MD

Aims: The aim of this study is to determine the most accurate renal function formula that predicts short- and long-term mortality in a wide spectrum of acute coronary syndrome (ACS) patients.

01 mayo 2015

AMERICAN HEART JOURNAL. Cost comparison of transcatheter and operative closures of ostium secundum atrial septal defects

Michael L. O’Byrne, MD MSCE, Matthew J. Gillespie, MD, Russell T. Shinohara, PhD, Yoav Dori, MD, PhD, Jonathan J. Rome, MD, Andrew C. Glatz, MD, MSCE

Background: Clinical outcomes for transcatheter and operative closures of atrial septal defects (ASDs) are similar. Economic cost for each method has not been well described.

17 abril 2015

JOURNAL OF THE AMERICAN HEART ASSOCIATION. Kidney in Cardiovascular Disease. Preprocedural N‐Terminal Pro‐Brain Natriuretic Peptide (NT‐proBNP) Is Similar to the Mehran Contrast‐Induced Nephropathy (CIN) Score in Predicting CIN Following Elective Coronary Angiography

Yong Liu, MD; Yi‐ting He, MD; Ning Tan, MD; Ji‐yan Chen, MD; Yuan‐hui Liu, MD; Da‐hao Yang, MD; Shui‐Jin Huang, MD; Piao Ye, MD; Hua‐long Li, MD; Peng Ran, MD; Chong‐yang Duan, MD; Shi‐qun Chen, MS; Ying‐ling Zhou, MD; Ping‐Yan Chen, MS

Background: N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) has been associated with important risk factors for contrast‐induced nephropathy (CIN). However, few studies have investigated the predictive value of NT‐proBNP itself. This study investigated whether levels of preprocedural NT‐proBNP could predict CIN after elective coronary angiography as effectively as the Mehran CIN score.

10 abril 2015

JOURNAL OF THE AMERICAN HEART ASSOCIATION. Health Services and Outcomes Research. Effectiveness and Safety of Dabigatran and Warfarin in Real‐World US Patients With Non‐Valvular Atrial Fibrillation: A Retrospective Cohort Study

Julie C. Lauffenburger, PharmD, PhD; Joel F. Farley, PhD; Anil K. Gehi, MD; Denise H. Rhoney, PharmD, FCCP, FCCM, FNCS; M. Alan Brookhart, PhD; Gang Fang, PharmD, MS, PhD

Background: The recent availability of dabigatran, a novel oral anticoagulant, provided a new treatment option for stroke prevention in atrial fibrillation beyond warfarin, the main therapy for years. Little is known about their real‐world comparative effectiveness and safety, even less among patient demographic and clinical subgroups.

30 enero 2015

JOURNAL OF THE AMERICAN HEART ASSOCIATION. Coronary Heart Disease. Predictors of Long‐term Clinical Endpoints in Patients With Refractory Angina

Thomas J. Povsic, MD, PhD; Samuel Broderick, MS; Kevin J. Anstrom, PhD; Linda K. Shaw, MS; E. Magnus Ohman, MD; Eric L. Eisenstein, DBA; Peter K. Smith, MD; John H. Alexander, MD, MHS

Background: Clinical outcomes in patients with refractory angina (RA) are poorly characterized and variably described. Using the Duke Database for Cardiovascular Disease (DDCD), we explored characteristics that drive clinical endpoints in patients with class II to IV angina stabilized on medical therapy.

23 febrero 2015

JOURNAL OF THE AMERICAN HEART ASSOCIATION. Coronary Heart Disease. Implantable Cardioverter‐Defibrillator Therapy in Patients With Ventricular Fibrillation out of Hospital Cardiac Arrest Secondary to Acute Coronary Syndrome

Malini Madhavan, MBBS; Paul A. Friedman, MD; Ryan J. Lennon, MS; Abhiram Prasad, MD; Roger D. White, MD; Chenni S. Sriram, MD; Rajiv Gulati, MD; Bernard J. Gersh, MBChB, DPhil, FRCP

Background: Survivors of ventricular fibrillation out of hospital cardiac arrest (VF‐OHCA) due to a potentially reversible cause such as acute myocardial infarction (MI) or ischemia are considered to be at low risk of recurrent arrhythmia. Implantable cardioverter defibrillators (ICD) are not routinely recommended in such patients. However, the outcome of these patients in the era of rapid coronary revascularization and ICD therapy is not known.

01 mayo 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Activated Clotting Time and Outcomes During Percutaneous Coronary Intervention for Non–ST-Segment–Elevation Myocardial Infarction

Gregory Ducrocq, MD, Sanjit Jolly, MD, Shamir R. Mehta, MD, Sunil V. Rao, MD, Tejas Patel, MD, Raul Moreno, MD, Peggy Gao, MSc and Philippe Gabriel Steg, MD

Background: Activated clotting time (ACT) is widely used to guide unfractionated heparin dosing during percutaneous coronary intervention. However, its value in predicting complications is controversial in the modern era. We sought to examine the relationship between ACT and outcomes in non–ST-segment–elevation acute coronary syndrome patients.

01 mayo 2015

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Myocardial Infarction Complete Versus Culprit-Only Revascularization for ST-Segment–Elevation Myocardial Infarction and Multivessel Disease

Sripal Bangalore, MD, MHA, Bora Toklu, MD and Jørn Wetterslev, MD, PhD

Background: The 2013 American College of Cardiology Foundation/American Heart Association guidelines for patients with ST-segment–elevation myocardial infarction gives a class III indication for nonculprit artery percutaneous coronary intervention at the time of primary percutaneous coronary intervention, driven by data from observational studies. However, more recent trials suggest otherwise.

25 febrero 2014

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Identifying Patients Who Do Not Benefit From Transcatheter Aortic Valve Replacement

Howard C. Herrmann, MD and Yuchi Han, MD

Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of patients with severe and symptomatic aortic stenosis.